JP2023549394A5 - - Google Patents

Info

Publication number
JP2023549394A5
JP2023549394A5 JP2023528637A JP2023528637A JP2023549394A5 JP 2023549394 A5 JP2023549394 A5 JP 2023549394A5 JP 2023528637 A JP2023528637 A JP 2023528637A JP 2023528637 A JP2023528637 A JP 2023528637A JP 2023549394 A5 JP2023549394 A5 JP 2023549394A5
Authority
JP
Japan
Prior art keywords
adhd
compound
use according
administered
interventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549394A (ja
Filing date
Publication date
Priority claimed from GBGB2017858.8A external-priority patent/GB202017858D0/en
Priority claimed from GBGB2103400.4A external-priority patent/GB202103400D0/en
Application filed filed Critical
Priority claimed from PCT/EP2021/081567 external-priority patent/WO2022101435A1/en
Publication of JP2023549394A publication Critical patent/JP2023549394A/ja
Publication of JP2023549394A5 publication Critical patent/JP2023549394A5/ja
Pending legal-status Critical Current

Links

JP2023528637A 2020-11-12 2021-11-12 注意欠陥／多動性障害の新規な治療 Pending JP2023549394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2017858.8 2020-11-12
GBGB2017858.8A GB202017858D0 (en) 2020-11-12 2020-11-12 Novel treatments
GBGB2103400.4A GB202103400D0 (en) 2021-03-11 2021-03-11 Novel treatments
GB2103400.4 2021-03-11
PCT/EP2021/081567 WO2022101435A1 (en) 2020-11-12 2021-11-12 Novel treatments of attention deficit/hyperactivity disorder

Publications (2)

Publication Number Publication Date
JP2023549394A JP2023549394A (ja) 2023-11-24
JP2023549394A5 true JP2023549394A5 (https=) 2024-11-19

Family

ID=78649316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528637A Pending JP2023549394A (ja) 2020-11-12 2021-11-12 注意欠陥／多動性障害の新規な治療

Country Status (4)

Country Link
US (1) US20240002369A1 (https=)
EP (1) EP4243826A1 (https=)
JP (1) JP2023549394A (https=)
WO (1) WO2022101435A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023084054A1 (en) * 2021-11-12 2023-05-19 3Z Ehf Treatment of adhd using selective binders of the 11-imidazoline receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
IL123232A0 (en) * 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
SK7222003A3 (en) * 2000-11-14 2004-05-04 Hoffmann La Roche Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as IP antagonists
AU2003251949A1 (en) * 2002-07-18 2004-02-09 Vanderbilt University Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype
CA2637292A1 (en) * 2006-01-27 2007-08-16 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders

Similar Documents

Publication Publication Date Title
AU2007213194B9 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
RU2478384C2 (ru) Курс лечения с использованием агониста рецептора s1p
US20090023712A1 (en) Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
US20060258640A1 (en) Use of Flibanserin in the treatment of chronic pain
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
EP1858516A1 (en) Pharmaceutical compositions for the treatment and/or prevention of depression
ES2350103T3 (es) Asociación de un antagonista o agonista inverso del receptor h3 de la histamina con un antipsicótico o un antidepresivo y su uso para preparar un medicamento que evite los efectos indeseables de los fármacos psicotropos.
JP2008521827A5 (https=)
BR112020016500A2 (pt) Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
US20130172304A1 (en) Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
JP7151029B2 (ja) 精神障害の治療における使用のためのイロペリドン代謝物
JP2024096962A (ja) ポネシモドを含有する医薬的組み合わせ
KR20210074315A (ko) P2x3 길항제를 사용한 소양증의 치료
JP6784407B2 (ja) 近視予防剤及び近視進行抑制剤
JP2023549394A5 (https=)
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
DK2694065T3 (en) COMPOSITION FOR TREATMENT OF DISORDER WITH SEXUAL SEXUAL LISTENING
WO2022087176A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
JP2007506784A (ja) 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
KR20190013847A (ko) 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물
RU2008108176A (ru) Комбинация соединений, которая может быть применена в лечении респеративных заболеваний, особенно хронического обструктивного заболевания легких (copd) и астмы
WO2024006841A2 (en) Compositions for weight loss and cancer treatment
JP2005531622A5 (https=)